Senate Health Committee Proposes Sweeping FDA Reforms to Speed Patient Access

By Sam Barron | Tuesday, February 17, 2026

Senate Health, Education, Labor, and Pensions (HELP) Committee Chair Sen. Bill Cassidy, R-La., has unveiled a report calling for modernization of the Food and Drug Administration (FDA) to expedite medical research and patient access to critical treatments.

The nearly 20-page report lists more than a dozen recommendations for improving how the FDA operates with Congress. Cassidy emphasized that biomedical innovation must translate into tangible health benefits for patients, stating: “Biomedical innovation holds enormous promise for the American people … But ‘innovation’ is meaningless unless it creates products that actually help patients.”

Cassidy noted that unnecessary bottlenecks in the FDA process slow down patients and consumers from receiving necessary medications. The committee chair said these delays are inconsistent with President Donald Trump’s mission to improve health outcomes for children and families.

“Ultimately, it should be easier to make Americans healthy by empowering them with the tools and information they need to make healthy choices and live better lives,” Cassidy added in the report.

Key recommendations include eliminating administrative hurdles to accelerate approvals of life-saving treatments, integrating artificial intelligence into review processes while maintaining safety standards, strengthening the FDA’s Human Foods Program for food safety, streamlining clinical trials to retain U.S. medical research leadership, and incentivizing top scientists to join the agency.

Cassidy, a physician, stated his goal is to “initiate a collaborative, bipartisan process for reforms to strengthen the FDA and get better and more affordable products to patients faster.”

The report also addresses challenges in drug approvals for rare diseases, noting that FDA review teams sometimes vary widely in their testing requirements and standards. Cassidy wrote: “FDA teams can differ greatly in the extent to which they require testing or impose standards that are not calibrated to the relevant risks.” He further observed that “the perceived disconnect between the forward leaning rhetoric and thought leadership of senior FDA officials and cautious reviewer practice creates further unpredictability.”